Evidence map›Paper›PMID 34944891›Full record

ArticleCancers2021

The Transmembrane Receptor TIRC7 Identifies a Distinct Subset of Immune Cells with Prognostic Implications in Cholangiocarcinoma.

Thomas Albrecht, Benjamin Goeppert, Fritz Brinkmann, Alphonse Charbel, Qiangnu Zhang, Johannes Schreck, Nina Wilhelm, Stephan Singer, Bruno C Köhler, Christoph Springfeld and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Thomas AlbrechtInstitute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany.ORCID 0000-0002-2234-0909
Benjamin GoeppertInstitute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany.
Fritz BrinkmannInstitute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany.ORCID 0000-0002-6663-0940
Alphonse CharbelInstitute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany.ORCID 0000-0002-7383-1898
Qiangnu ZhangInstitute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany.
Johannes SchreckInstitute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany.
Nina WilhelmTissue Bank of the National Center for Tumor Diseases, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Stephan SingerInstitute of Pathology and Neuropathology, Eberhard-Karls University, 72076 Tübingen, Germany.
Bruno C KöhlerLiver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany.
Christoph SpringfeldLiver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany.
Arianeb MehrabiLiver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany.
Peter SchirmacherInstitute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany.
Anja A KühlCharité-Universitätsmedizin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, iPATH.Berlin, 12203 Berlin, Germany.ORCID 0000-0003-2293-5387
Monika N VogelDiagnostic and Interventional Radiology, Thoraxklinik at Heidelberg University Hospital, 69126 Heidelberg, Germany.
Holger JansenInstitute for Medical Immunology, Campus Virchow, Charité, Augustenburger Platz 1, 13353 Berlin, Germany.
Nalân UtkuInstitute for Medical Immunology, Campus Virchow, Charité, Augustenburger Platz 1, 13353 Berlin, Germany.
Stephanie RoesslerInstitute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany.ORCID 0000-0002-5333-5942
Heidelberg University · DECharité - Universitätsmedizin Berlin · DEHumboldt-Universität zu Berlin · DEUniversity of Tübingen · DE

Funding

Deutsche Forschungsgemeinschaft 314905040German Cancer Aid 70113922The European Union's Horizon 2020 research and innovation programme under Eurostars E! 113707 LiverQR
6 · The paper itself

Abstract

Cholangiocarcinoma (CCA) is a heterogeneous malignancy with a dismal prognosis. Therapeutic options are largely limited to surgery and conventional chemotherapy offers limited benefit. As immunotherapy has proven highly effective in various cancer types, we have undertaken a quantitative immunohistopathological assessment of immune cells expressing the immunoinhibitory T cell immune response cDNA 7 receptor (TIRC7), an emerging immunoinhibitory receptor, in a cohort of 135 CCA patients. TIRC7

Indexed as

biomarkerscholangiocarcinomaimmune checkpoint inhibitorsimmunotherapyPD-L1TIRC7tumor microenvironment

Identifiers

PMID34944891
PMCPMC8699724
OpenAlexW4200312987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.